Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 66


Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature.

Peck MW, Smith TJ, Anniballi F, Austin JW, Bano L, Bradshaw M, Cuervo P, Cheng LW, Derman Y, Dorner BG, Fisher A, Hill KK, Kalb SR, Korkeala H, Lindström M, Lista F, Lúquez C, Mazuet C, Pirazzini M, Popoff MR, Rossetto O, Rummel A, Sesardic D, Singh BR, Stringer SC.

Toxins (Basel). 2017 Jan 18;9(1). pii: E38. doi: 10.3390/toxins9010038. Review.


Chromatin remodeling inactivates activity genes and regulates neural coding.

Yang Y, Yamada T, Hill KK, Hemberg M, Reddy NC, Cho HY, Guthrie AN, Oldenborg A, Heiney SA, Ohmae S, Medina JF, Holy TE, Bonni A.

Science. 2016 Jul 15;353(6296):300-305. doi: 10.1126/science.aad4225.


Genetic diversity within the botulinum neurotoxin-producing bacteria and their neurotoxins.

Hill KK, Xie G, Foley BT, Smith TJ.

Toxicon. 2015 Dec 1;107(Pt A):2-8. doi: 10.1016/j.toxicon.2015.09.011. Epub 2015 Sep 11.


Genomic sequences of six botulinum neurotoxin-producing strains representing three clostridial species illustrate the mobility and diversity of botulinum neurotoxin genes.

Smith TJ, Hill KK, Xie G, Foley BT, Williamson CH, Foster JT, Johnson SL, Chertkov O, Teshima H, Gibbons HS, Johnsky LA, Karavis MA, Smith LA.

Infect Genet Evol. 2015 Mar;30:102-13. doi: 10.1016/j.meegid.2014.12.002. Epub 2014 Dec 6.


Historical and current perspectives on Clostridium botulinum diversity.

Smith TJ, Hill KK, Raphael BH.

Res Microbiol. 2015 May;166(4):290-302. doi: 10.1016/j.resmic.2014.09.007. Epub 2014 Oct 12. Review.


Molecular epidemiology of infant botulism in California and elsewhere, 1976-2010.

Dabritz HA, Hill KK, Barash JR, Ticknor LO, Helma CH, Dover N, Payne JR, Arnon SS.

J Infect Dis. 2014 Dec 1;210(11):1711-22. doi: 10.1093/infdis/jiu331. Epub 2014 Jun 12.


Arrangement of the Clostridium baratii F7 toxin gene cluster with identification of a σ factor that recognizes the botulinum toxin gene cluster promoters.

Dover N, Barash JR, Burke JN, Hill KK, Detter JC, Arnon SS.

PLoS One. 2014 May 22;9(5):e97983. doi: 10.1371/journal.pone.0097983. eCollection 2014.


Molecular characterization of a novel botulinum neurotoxin type H gene.

Dover N, Barash JR, Hill KK, Xie G, Arnon SS.

J Infect Dis. 2014 Jan 15;209(2):192-202. doi: 10.1093/infdis/jit450. Epub 2013 Oct 7.


Type I IFNs downregulate myeloid cell IFN-γ receptor by inducing recruitment of an early growth response 3/NGFI-A binding protein 1 complex that silences ifngr1 transcription.

Kearney SJ, Delgado C, Eshleman EM, Hill KK, O'Connor BP, Lenz LL.

J Immunol. 2013 Sep 15;191(6):3384-92. doi: 10.4049/jimmunol.1203510. Epub 2013 Aug 9.


Clostridium botulinum strain Af84 contains three neurotoxin gene clusters: bont/A2, bont/F4 and bont/F5.

Dover N, Barash JR, Hill KK, Davenport KW, Teshima H, Xie G, Arnon SS.

PLoS One. 2013 Apr 12;8(4):e61205. doi: 10.1371/journal.pone.0061205. Print 2013.


Cerebral blood flow responses to dorsal and ventral STN DBS correlate with gait and balance responses in Parkinson's disease.

Hill KK, Campbell MC, McNeely ME, Karimi M, Ushe M, Tabbal SD, Hershey T, Flores HP, Hartlein JM, Lugar HM, Revilla FJ, Videen TO, Earhart GM, Perlmutter JS.

Exp Neurol. 2013 Mar;241:105-12. doi: 10.1016/j.expneurol.2012.12.003. Epub 2012 Dec 19.


Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes.

Hill KK, Smith TJ.

Curr Top Microbiol Immunol. 2013;364:1-20. doi: 10.1007/978-3-642-33570-9_1.


Genomic comparison of Escherichia coli O104:H4 isolates from 2009 and 2011 reveals plasmid, and prophage heterogeneity, including shiga toxin encoding phage stx2.

Ahmed SA, Awosika J, Baldwin C, Bishop-Lilly KA, Biswas B, Broomall S, Chain PS, Chertkov O, Chokoshvili O, Coyne S, Davenport K, Detter JC, Dorman W, Erkkila TH, Folster JP, Frey KG, George M, Gleasner C, Henry M, Hill KK, Hubbard K, Insalaco J, Johnson S, Kitzmiller A, Krepps M, Lo CC, Luu T, McNew LA, Minogue T, Munk CA, Osborne B, Patel M, Reitenga KG, Rosenzweig CN, Shea A, Shen X, Strockbine N, Tarr C, Teshima H, van Gieson E, Verratti K, Wolcott M, Xie G, Sozhamannan S, Gibbons HS; Threat Characterization Consortium.

PLoS One. 2012;7(11):e48228. doi: 10.1371/journal.pone.0048228. Epub 2012 Nov 1.


Analysis of Clostridium botulinum serotype E strains by using multilocus sequence typing, amplified fragment length polymorphism, variable-number tandem-repeat analysis, and botulinum neurotoxin gene sequencing.

Macdonald TE, Helma CH, Shou Y, Valdez YE, Ticknor LO, Foley BT, Davis SW, Hannett GE, Kelly-Cirino CD, Barash JR, Arnon SS, Lindström M, Korkeala H, Smith LA, Smith TJ, Hill KK.

Appl Environ Microbiol. 2011 Dec;77(24):8625-34. doi: 10.1128/AEM.05155-11. Epub 2011 Oct 14.


An attenuated strain of Bacillus anthracis (CDC 684) has a large chromosomal inversion and altered growth kinetics.

Okinaka RT, Price EP, Wolken SR, Gruendike JM, Chung WK, Pearson T, Xie G, Munk C, Hill KK, Challacombe J, Ivins BE, Schupp JM, Beckstrom-Sternberg SM, Friedlander A, Keim P.

BMC Genomics. 2011 Sep 30;12:477. doi: 10.1186/1471-2164-12-477.


MPYS is required for IFN response factor 3 activation and type I IFN production in the response of cultured phagocytes to bacterial second messengers cyclic-di-AMP and cyclic-di-GMP.

Jin L, Hill KK, Filak H, Mogan J, Knowles H, Zhang B, Perraud AL, Cambier JC, Lenz LL.

J Immunol. 2011 Sep 1;187(5):2595-601. doi: 10.4049/jimmunol.1100088. Epub 2011 Aug 3.


Structural and functional analysis of domains of the progesterone receptor.

Hill KK, Roemer SC, Churchill ME, Edwards DP.

Mol Cell Endocrinol. 2012 Jan 30;348(2):418-29. doi: 10.1016/j.mce.2011.07.017. Epub 2011 Jul 22. Review.


Novel structural elements within the nonproteolytic clostridium botulinum type F toxin gene cluster.

Dover N, Barash JR, Hill KK, Detter JC, Arnon SS.

Appl Environ Microbiol. 2011 Mar;77(5):1904-6. doi: 10.1128/AEM.02422-10. Epub 2010 Dec 23.


Antagonistic crosstalk between type I and II interferons and increased host susceptibility to bacterial infections.

Rayamajhi M, Humann J, Kearney S, Hill KK, Lenz LL.

Virulence. 2010 Sep-Oct;1(5):418-22. doi: 10.4161/viru.1.5.12787. Review.


The acquired preparedness model of risk for bulimic symptom development.

Combs JL, Smith GT, Flory K, Simmons JR, Hill KK.

Psychol Addict Behav. 2010 Sep;24(3):475-86. doi: 10.1037/a0018257.

Supplemental Content

Support Center